Neratinib for Metastatic HER2+ Breast Cancer and Brain Metastases

Oncologists debate the use of neratinib for metastatic HER2+ breast cancer treatment in the context of the HER2CLIMB clinical trial data on tucatinib.

Related Videos
Experts on GVHD with a patient
Experts on GVHD with a patient
Experts on RCC
Experts on RCC
Experts on breast cancer
Experts on breast cancer
Experts on RCC
Experts on RCC
Related Content